Insider Selling: CeriBell (NASDAQ:CBLL) CEO Sells 25,000 Shares of Stock

CeriBell (NASDAQ:CBLL - Get Free Report) CEO Xingjuan Chao sold 25,000 shares of the firm's stock in a transaction on Tuesday, June 3rd. The shares were sold at an average price of $17.00, for a total transaction of $425,000.00. Following the completion of the sale, the chief executive officer now owns 776,022 shares in the company, valued at $13,192,374. The trade was a 3.12% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

Xingjuan Chao also recently made the following trade(s):

• On Thursday, May 15th, Xingjuan Chao sold 25,000 shares of CeriBell stock. The shares were sold at an average price of $16.96, for a total transaction of $424,000.00.
• On Wednesday, April 23rd, Xingjuan Chao sold 15,628 shares of CeriBell stock. The shares were sold at an average price of $15.11, for a total value of $236,139.08.
• On Thursday, April 17th, Xingjuan Chao sold 5,700 shares of CeriBell stock. The stock was sold at an average price of $15.02, for a total value of $85,614.00.
• On Monday, April 21st, Xingjuan Chao sold 3,372 shares of CeriBell stock. The stock was sold at an average price of $15.03, for a total value of $50,681.16.

CeriBell Stock Up 2.1%

CBLL stock traded up $0.36 during trading on Thursday, reaching $17.50. 275,327 shares of the company were exchanged, compared to its average volume of 280,863. CeriBell has a 52-week low of $10.01 and a 52-week high of $32.75. The stock's 50 day moving average price is $16.61 and its 200 day moving average price is $21.49.

CeriBell (NASDAQ:CBLL - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.36) EPS for the quarter, topping analysts' consensus estimates of ($0.43) by $0.07. The company had revenue of $20.49 million for the quarter, compared to analysts' expectations of $19.30 million. On average, research analysts expect that CeriBell will post -2.46 earnings per share for the current fiscal year.

Hedge Funds Weigh In On CeriBell

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CBLL. FMR LLC acquired a new position in shares of CeriBell in the fourth quarter valued at approximately $128,120,000. TPG GP A LLC acquired a new position in CeriBell during the fourth quarter worth approximately $102,677,000. Red Tree Management LLC acquired a new position in CeriBell during the fourth quarter worth approximately $57,083,000. Yu Fan acquired a new position in CeriBell during the fourth quarter worth approximately $31,631,000. Finally, ABG WTT Global Life Science Capital Partners GP Ltd acquired a new position in CeriBell during the fourth quarter worth approximately $28,160,000.

Wall Street Analyst Weigh In

A number of research firms recently issued reports on CBLL. LADENBURG THALM/SH SH started coverage on CeriBell in a research note on Friday, April 4th. They set a "buy" rating and a $32.00 price target on the stock. Canaccord Genuity Group reissued a "buy" rating and set a $33.00 price objective on shares of CeriBell in a research report on Wednesday, February 26th. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has a consensus rating of "Buy" and an average target price of $32.50.

About CeriBell

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.